

# HEALTH AND SATISFACTION RESULTS REPORTED BY PATIENTS, AFTER A TREATMENT BASED ON A MODIFIED *DERMATOPHAGOIDES PTERONYSSINUS* EXTRACT ASSOCIATED WITH MICROCRYSTALLINE TYROSINE (MCT)


Malet A.<sup>1</sup>, Moreno V.<sup>2</sup>, De la Roca F.<sup>3</sup>, Roger A.<sup>4</sup>, Boronat A.<sup>5</sup>, Justicia J.L.<sup>5</sup>

<sup>1</sup>Al-Iergo Centre, Barcelona, Spain; <sup>2</sup>Centro de Especialidades Médicas Integradas, Huelva, Spain; <sup>3</sup>H. Clínic de Barcelona, Barcelona, Spain; <sup>4</sup>H. Germans Trias i Pujol, Badalona; <sup>5</sup>Allergy Therapeutics, Worthing, United Kingdom

## INTRODUCTION

An extract of *D. pteronyssinus* modified with glutaraldehyde and associated with MCT has previously exhibited tolerance and effectiveness in patients with allergic rhinitis and bronchial asthma, caused by *Dermatophagoides*. The objective of this sub-analysis was to assess the quality life of patients, the self-perceived intensity of the disease and patients' satisfaction with the treatment.

## METHOD




This trial was a prospective, observational and multi-centre study in adult patients with allergic rhinitis with or without asthma caused by *Dermatophagoides*, who received immunotherapy with a MCT-adjuvanted polymerised extract (*D. pteronyssinus* [DP] 100%), for 1 year.

Analysed parameters included quality of life (ESPRINT-15 questionnaire and AQLQ questionnaire in patients with asthma), symptom intensity evaluated by patients (visual analogue scale, VAS) and satisfaction with the treatment (TSQM questionnaire, Treatment Satisfaction Questionnaire for Medication).

Of 118 evaluable patients:  
58.8% female; 43.2% male  
Mean age: 33.6 ± 9.5 years  
Rhinitis: 100%; Disease duration: 11.7 years  
Asthma: 46.6%; Disease duration: 14.1 years


## RESULTS

### Rhinitis Quality of Life (ESPRINT-15)




Rhinitis-related quality of life measured by the SPRINT-15 questionnaire (global score) improved from 2.62 (baseline) to 1.33 (6 months) and 1.16 (1 year) (p<0.0001).

### Asthma Quality of Life (AQLQ)




Asthma-related quality of life measured by the AQLQ questionnaire (total score) improved from (total score): 3.03 (baseline) vs. 1.23 (6 months) vs. 1.45 (1 year) (p<0.0001).

### Self-reported symptom intensity (VAS)



Intensity of symptoms assessed by a VAS decreased from 6.41 (baseline) to 3.47 (6 months) and 2.48 (1 year) (p<0.0001).

### Treatment Satisfaction (TSQM)



No significant differences in treatment satisfaction between 6-months and 1-year treatment. The global satisfaction with the treatment (TSQM) were 71.7 points at 6 months and 73.4 points at 1 year.

## REFERENCES

- Valero A *et al*, EPRINT Study Group. EPRINT-15 questionnaire (Spanish version): J Investig Allergol Clin Immunol. 2013;23(1):14-9.
- Roger A *et al*. A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy. Immun Inflamm Dis. 2014; 2(2):92-98.
- Roger A *et al*. A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report. immunotherapy 2016; 8(10):1169-74.
- Roger A *et al*. EAACI 2018 (Póster). Immunological and clinical changes after 1-year treatment with a tyrosine-adsorbed mite allergoid: preliminary results.

## CONCLUSIONS

Specific immunotherapy with a house dust mite allergoid associated with MCT, in patients allergic to *Dermatophagoides*, showed improvement in health-related outcomes as reported by patients (Quality of Life and VAS) along with a high satisfaction with the treatment.